TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$60 Million


Follow-on Offering

Lead Left Bookrunner, September 2016

Confidentially Marketed Public Offering

Aravive Biologics is a private clinical stage biopharmaceutical company developing novel, selective therapies designed to treat serious cancers and fibrotic diseases.  Aravive’s lead program, AVB-S6-500, is a GAS6-AXL pathway inhibitor in development for the treatment of multiple cancers.  GAS6-AXL signal inhibition has the potential to overcome tumor resistance and increase the efficacy of anti-cancer agents. In several preclinical studies, AVB-S6-500 has shown anti-tumor activity as a single agent and in combination with current standard of care oncolytics and has also exhibited potential as a treatment strategy for certain fibrotic diseases. AVB-S6-500 has demonstrated proof-of-mechanism and a favorable tolerability profile in an ongoing Phase I study.  Aravive anticipates initiating a Phase Ib/II combination study with standard of care therapies initially in platinum-resistant ovarian cancer in the second half of 2018. The combined entity will have the necessary capital and leadership in place to advance the clinical development program through multiple inflection points over the next two years.